hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06334016 id: I-3597023 id: NCI-2024-01556 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: I-3597023 type: OTHER domain: Roswell Park Cancer Institute id: R01DA057228 type: NIH link: https://reporter.nih.gov/quickSearch/R01DA057228 briefTitle: Evaluating the Delivery and Effects of THC Vaping Liquids in the Bloodstream overallStatus: NOT_YET_RECRUITING date: 2025-03-27 date: 2028-03-01 date: 2028-03-01 date: 2024-03-27 date: 2024-03-27 name: Roswell Park Cancer Institute class: OTHER name: National Institute on Drug Abuse (NIDA) briefSummary: This clinical trial assesses differences in the delivery of THC to the bloodstream depending on whether nicotine vapes are used before or after THC. While there has been much recent publicity about vaping products and concern about their safety considering their increasing use for THC administration, the THC delivery profile associated with THC liquid vaping products in human subjects is currently unknown. Importantly, how the delivery to the bloodstream of THC vaping liquids compare to delivery from smoked cannabis, which is the most used method of cannabis delivery, will serve as an important benchmark for evaluating the delivery and effects of THC vaping products, and their relative safety. conditions: Cannabis Dependence studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: Within-subject crossover study primaryPurpose: BASIC_SCIENCE masking: QUADRUPLE maskingDescription: Both participants and clinical personnel will be blinded to the nicotine product sequence (active vs. placebo). whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Biospecimen Collection name: Cannabis sativa Extract name: Nicotine name: Placebo Administration name: Questionnaire Administration measure: Maximum concentration of THC in plasma (Cmax) measure: Area under the plasma concentration-time curve from 0-360 minutes (AUC0-360) measure: Time to maximum concentration of THC in plasma (Tmax) measure: Incidence of adverse events (AEs) measure: Puffing behaviors measure: Puffing behaviors measure: Short-term drug effects measure: Marijuana Withdrawal Checklist [MWC) measure: Digit Symbol Substitution Task (DSST) measure: Paced Auditory Serial Addition Task (PASET) measure: Tobacco Craving Questionnaire (Short Form) sex: ALL minimumAge: 21 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Roswell Park Cancer Institute city: Buffalo state: New York zip: 14263 country: United States name: Danielle M. Smith role: CONTACT phone: 716-845-8403 email: Danielle.Smith@RoswellPark.org name: Danielle M. Smith role: PRINCIPAL_INVESTIGATOR lat: 42.88645 lon: -78.87837 hasResults: False
nctId: NCT06334003 id: H-23071266 briefTitle: Cardiometabolic Function in Offspring, Mother and Placenta After Assisted Reproductive Technology acronym: COMPART overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-04-30 date: 2027-12-01 date: 2024-03-27 date: 2024-03-27 name: Rigshospitalet, Denmark class: OTHER name: Herlev Hospital briefSummary: The overall objective is to establish the first-of-its-kind longitudinal cohort of pregnant women, biological fathers/partners and offspring from pregnancies achieved by frozen embryo transfer (FET), fresh-embryo transfer (fresh ET) and naturally conceived (NC) to investigate maternal cardiometabolic profiles, fetal growth patterns and placental function during pregnancy as well as metabolic and endocrine health in the offspring. Additionally, the aim is to explore genetic and epigenetic patterns in placenta, fetus and parents. As secondary objectives, the investigator group will examine telomere length and minipuberty hormones in children born after FET, fresh-ET and NC. conditions: ART conditions: IVF conditions: Children, Only conditions: Cardiovascular Disease Other studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 600 type: ESTIMATED measure: Offspring body composition measure: Maternal cardiometabolic profile measure: Epigenetic in placenta and cord blood measure: Early markers of reproductive function in FET, fresh-ET and NC children: LH, FSH, SHBG, AMH, androgens, estrogens (SDS) measure: Telomere length in children born after FET, fresh-ET and NC children sex: ALL minimumAge: 18 Years maximumAge: 40 Years stdAges: ADULT facility: Fertility Clinic, Rigshospitalet, Copenhagen University Hospital city: Copenhagen zip: 2100 country: Denmark lat: 55.67594 lon: 12.56553 facility: Dept. of Paediatric and Adolescent Medicine, Herlev Hospital city: Copenhagen country: Denmark name: Rikke B. Jensen, MD, Ass. Prof role: CONTACT name: Maria L. Vestager, MD, PhD-student role: CONTACT email: maria.linander.vestager.01@regionh.dk lat: 55.67594 lon: 12.56553 hasResults: False
nctId: NCT06333990 id: 20220796HU briefTitle: Quetiapine to Reduce Post Concussive Syndrome After Mild Traumatic Brain Injury (mTBI) overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2028-03 date: 2028-03 date: 2024-03-27 date: 2024-03-27 name: Foundation for Advancing Veterans' Health Research class: OTHER name: The University of Texas Health Science Center at San Antonio name: Biomedical Research Institute of New Mexico briefSummary: A two site, 2-arm, Phase III randomized pragmatic clinical trial evaluating the effectiveness of quetiapine monotherapy in comparison to Treatment As Usual (TAU) medication management for symptoms experienced by veterans receiving rehabilitation therapy for mild traumatic brain injury (mTBI) and comorbid symptoms of posttraumatic stress disorder (PTSD). conditions: Mild Traumatic Brain Injury studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 146 type: ESTIMATED name: Quetiapine Fumarate name: TAU measure: Neurobehavioral Symptom Inventory measure: World Health Organization Disability Assessment Scale measure: World Health Organization Quality of Life BREF sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06333977 id: LG-GQCL001 briefTitle: A Study of LC542019 in Healthy Subjects and Subjects With T2DM overallStatus: COMPLETED date: 2022-03-25 date: 2023-12-14 date: 2023-12-14 date: 2024-03-27 date: 2024-03-27 name: LG Chem class: INDUSTRY briefSummary: to assess the safety, tolerability, Pharmacokinetics and Pharmacodynamics in healthy subjects and subjects with type 2 diabetes (T2DM). conditions: Healthy conditions: Diabetes Mellitus, Type 2 studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 100 type: ACTUAL name: LC542019 name: Placebo measure: Incidence, severity of adverse events measure: Maximum Concentration (Cmax) in Plasma measure: Renal Clearance (CLR) in urine measure: Cardiodynamic evaluation measure: Fasting Plasma Glucose measure: HbA1c sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: PPD Development, LP (PPD Clinical Research Unit, Las Vegas) city: Las Vegas state: Nevada zip: 89113 country: United States lat: 36.17497 lon: -115.13722 hasResults: False
nctId: NCT06333964 id: AST-001P_P301_ASD briefTitle: Phase III Clinical Trial to Evaluate the Efficacy and Safey of AST-001 in ASD Children overallStatus: RECRUITING date: 2023-08-29 date: 2024-09-30 date: 2024-12-31 date: 2024-03-27 date: 2024-03-27 name: Astrogen, Inc. class: INDUSTRY briefSummary: 1. Study purpose: To demonstrate the superiority of AST-001 compared to placebo in improving core symptoms of autism spectrum disorder (ASD) in children with ASD.
2. Background: ASD is a neurodevelopmental disorder characterized by deficits in social communication and social interaction as well as restricted, repetitive patterns of behavior, interests, or activities. There are no approved medicines to treat the core symptom of ASD. Although these drugs and other psychotropic medications are associated with side effects, the use of psychotropic drugs to treat associated psychiatric comorbidities is common. AST-001 is developed to treat the core symptom of ASD.
3. Design: Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 clinical trial followed by an Open-Label Extension Treatment Period conditions: Autism Spectrum Disorder studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Main study(0\~12 weeks) Experimental: AST-001 Comparator: Placebo of AST-001
Extension study(12\~24 weeks) Experimental: AST-001 Comparator: AST-001 primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 160 type: ESTIMATED name: AST-001 name: Placebo of AST-001 measure: K-VABS-II (Korean-Vineland Adaptive Behavior Scale-II) measure: CGI (Clinical Global Impression) measure: SRS-2 (Social Responsiveness Scale-2) measure: K-PSI-4-SF (Korean-Parenting Stress Index-4th Edition Short Form) sex: ALL minimumAge: 2 Years maximumAge: 7 Years stdAges: CHILD facility: Soon Chun Hyang University Hospital Cheonan status: RECRUITING city: Cheonan state: Chungcheongnam-do country: Korea, Republic of lat: 36.8065 lon: 127.1522 facility: Hallym University Medical Center status: RECRUITING city: Anyang state: Gyeonggi-do country: Korea, Republic of lat: 37.3925 lon: 126.92694 facility: Samsung Changwon Medical Center status: RECRUITING city: Changwon state: Gyeongsangnam-do country: Korea, Republic of lat: 35.22806 lon: 128.68111 facility: Pusan National University Yangsan Hospital status: RECRUITING city: Yangsan state: Gyeongsangnam-do country: Korea, Republic of lat: 35.34199 lon: 129.03358 facility: Jeonbuk National University Hospital status: RECRUITING city: Jeonju state: Jeollabuk-do country: Korea, Republic of lat: 35.82194 lon: 127.14889 facility: Chungnam National University Hospital status: RECRUITING city: Daejeon country: Korea, Republic of lat: 36.32139 lon: 127.41972 facility: Asan Medical Center status: RECRUITING city: Seoul country: Korea, Republic of lat: 37.566 lon: 126.9784 facility: Hanyang University Seoul Hospital status: RECRUITING city: Seoul country: Korea, Republic of lat: 37.566 lon: 126.9784 facility: Koera University Guro Hospital status: RECRUITING city: Seoul country: Korea, Republic of lat: 37.566 lon: 126.9784 facility: Samsung Medical Center status: RECRUITING city: Seoul country: Korea, Republic of lat: 37.566 lon: 126.9784 facility: The Catholic University of Korea, Seoul St. Mary's Hospital status: RECRUITING city: Seoul country: Korea, Republic of lat: 37.566 lon: 126.9784 hasResults: False
nctId: NCT06333951 id: 20230167 briefTitle: AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) overallStatus: RECRUITING date: 2024-06-03 date: 2026-10-08 date: 2029-10-07 date: 2024-03-27 date: 2024-04-25 name: Amgen class: INDUSTRY briefSummary: The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted thoracic tumors. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted thoracic tumors. conditions: Thoracic Tumors conditions: Non-small Cell Lung Cancer studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 500 type: ESTIMATED name: AMG 193 name: Carboplatin name: Paclitaxel name: Pembrolizumab name: Pemetrexed name: Sotorasib measure: Number of Participants Experiencing Dose Limiting Toxicities (DLT) measure: Number of Participants Experiencing Treatment Emergent Adverse Events (TEAE) measure: Number of Participants Experiencing Serious Adverse Events (SAE) measure: Objective Response (OR) per Response Evaluation Criteria in Solid Tumors (RECIST v1.1) measure: Disease Control (DC) per RECIST v1.1 measure: Duration of Response (DOR) per RECIST v1.1 measure: Time to Response (TTR) per RECIST v1.1 measure: Overall Survival (OS) per RECIST v1.1 measure: Progression-free Survival (PFS) per RECIST v1.1 measure: Maximum Plasma Concentration (Cmax) of AMG 193 measure: Time to Maximum Plasma Concentration (tmax) of AMG 193 measure: Area Under the Plasma Concentration-time Curve (AUC) of AMG 193 measure: Intracranial objective response (IOR) per Response Assessment in Neuro Oncology Brain Metastases (RANO-BM ) measure: Intracranial Disease Control (IDC) per RANO-BM measure: Intracranial Duration of Response (IDOR) per RANO-BM measure: Time to Intracranial Radiation Therapy per RANO-BM sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: City of Hope (COH) status: RECRUITING city: Duarte state: California zip: 91010 country: United States lat: 34.13945 lon: -117.97729 hasResults: False
nctId: NCT06333938 id: 01968 briefTitle: Veterans Enhanced Recovery Using Integrative Treatments Around Surgery acronym: VERITAS overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2024-12 date: 2025-06 date: 2024-03-27 date: 2024-03-27 name: Durham VA Medical Center class: FED briefSummary: The study aims to assess the effectiveness of NSS2-Bridge in postoperative pain management in comparison to Battlefield Acupuncture (BFA). conditions: Anesthesia conditions: Surgery conditions: Knee Arthropathy studyType: INTERVENTIONAL phases: PHASE4 allocation: NON_RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: Bridge name: BFA measure: Pain and Pain Interference assessed among patients using the Defense veterans pain rating scale 2.0 measure: Heart Rate Variability among Patients as assessed using time and frequency domain analysis of the heart rate. measure: Implementation of Treatment among Patients as assessed by the Acceptability of Intervention, Appropriateness of Intervention, and Feasibility of Intervention Measures. measure: Fidelity of Treatment among Patients as assessed by a Fidelity Checklist measure: Implementation of Treatment among Providers as assessed by the Acceptability of Intervention, Appropriateness of Intervention, and Feasibility of Intervention Measures. measure: Fidelity of Treatment among Providers as assessed by a Fidelity Checklist measure: Amount of Opioid medication received by patients assessed in average daily oral morphine equivalents. measure: Quality of Recovery among patients as measured using the Quality-of-Recovery 40 tool. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06333925 id: Pro00114183 briefTitle: Using Neurostimulation to Accelerate Change in Misophonia: a Pilot Study acronym: MISO-STIM overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-10-31 date: 2026-10-31 date: 2024-03-27 date: 2024-03-27 name: Duke University class: OTHER name: Misophonia Research Fund briefSummary: Misophonia, the inability to tolerate certain repetitive distressing sounds that are common, is gaining, recognition as an impairing condition. It is not a well-understood condition and there are no known treatments. The purpose of this study is to test a new misophonia intervention that uses emotion regulation strategies and different types of brain stimulation on misophonic distress. This study will examine changes in brain activity during presentation and regulation of misophonic versus distressing sounds. The study team plans to alter activity in a key area of the brain responsible for emotion regulation circuitry over 4 sessions with the goal to test if this intervention helps misophonic distress.
Sixty adult participants with moderate to severe misophonia will be recruited and taught an emotion regulation skill and randomly assigned to receive one of two types of repetitive transcranial magnetic stimulation (rTMS). The study includes 9-10 visits: the remote screening visit(s), the initial MRI, the four neurostimulation sessions, the follow-up MRI, and two additional remote 1- and 3-month follow-up visits. conditions: Misophonia conditions: Emotion Dysregulation conditions: Sensory Processing Disorder conditions: Auditory Over Responsivity conditions: Anxiety Disorder conditions: Sound Sensitivity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: In regards to the neurostimulation used in the study, there will be two conditions, receiving either active or sham neurostimulation. Both conditions will receive behavioral training in cognitive restructuring (CR; a type of emotion regulation skill). Randomization procedures will match participants on age, gender at birth, and misophonia impairment severity. primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: All participants will engage in a behavioral training session (Cognitive Restructuring).
Participants will only be told about the type of neurostimulation at the end of the study to protect against different expectations whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 60 type: ESTIMATED name: High Frequency Repetitive Transcranial Magnetic Stimulation (HF rTMS) name: Sham Repetitive Transcranial Magnetic Stimulation (sham- rTMS) name: Cognitive Restructuring measure: Number of clusters across the whole brain with significant BOLD changes between conditions contrasting follow up with intake, and exposure to misophonic versus aversive sounds measure: Number of clusters across the whole brain with significant BOLD changes between conditions contrasting follow up with intake, and downregulation of versus exposure to misophonic sounds measure: Differential change in BOLD signal within the Anterior Insular Cortex (AIC) activation when being presented with misophonic versus non-misophonic but aversive sounds measure: Differential change in BOLD signal connectivity between the left Anterior Insular Cortex (AIC) and the right dorsolateral prefrontal cortex (dlPFC) when downregulating versus experiencing distress related to misophonic trigger sounds measure: Change in misophonia impairment and severity using a composite measure: Skin conductance level (scl) measure: Change in Subjective Unites of Distress (SUDS) measure: Changes in self-reported psychopathology measure: Changes in clinician-assessed psychopathology measure: Emotional dysregulation as measured by the Difficulties in Emotion Regulation Scale (DERS) measure: Changes in self-reported cognitive flexibility measure: Changes in self-reported cognitive skills measure: Baseline emotional dysregulation measure: Baseline hyperacusis measure: Baseline Affect Intensity measure: Change in Emotional distress measure: Change in self-reported Emotion regulation measure: Change in Sensory sensitivity measure: Change in Interoceptive Awareness sex: ALL minimumAge: 18 Years maximumAge: 55 Years stdAges: ADULT facility: Duke University Medical Center city: Durham state: North Carolina zip: 27710 country: United States name: Jessica Choi, MA role: CONTACT phone: 919-684-4432 email: jessica.choi@duke.edu name: Lisalynn D Kelley, BA, CCRP role: CONTACT phone: 919-684-6701 email: lisalynn.kelley@duke.edu name: Andrada D Neacsiu, PhD role: PRINCIPAL_INVESTIGATOR lat: 35.99403 lon: -78.89862 hasResults: False
nctId: NCT06333912 id: ridgesplittingguided briefTitle: Accuracy of Guided Ridge Splitting With Simultaneous Implant Placement overallStatus: COMPLETED date: 2023-08-02 date: 2024-01-29 date: 2024-02-27 date: 2024-03-27 date: 2024-03-27 name: Alexandria University class: OTHER briefSummary: Assessing whether is there a difference between computer-guided ridge splitting and conventional technique with simultaneous implant placement in patients with maxillary width deficiency. conditions: Dental Implant studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 12 type: ACTUAL name: dental implant placement with ridge splitting. measure: Assessing the accuracy of guided surgery measure: the bone-width increase between control and study group. sex: ALL minimumAge: 20 Years maximumAge: 60 Years stdAges: ADULT facility: Alexandria University, Faculty of dentistry city: Alexandria zip: 21619 country: Egypt lat: 31.21564 lon: 29.95527 hasResults: False
nctId: NCT06333886 id: ciusss-nordmtl_ESG briefTitle: Use of Point-of-care Neuro-sacral Electrophysiology Following Spinal Cord Injury overallStatus: ACTIVE_NOT_RECRUITING date: 2024-03-18 date: 2028-12-31 date: 2028-12-31 date: 2024-03-27 date: 2024-03-27 name: Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal class: OTHER briefSummary: Assessing the sacral nerves is an integral aspect of the evaluation after a spinal cord injury. Being located at the lower end of the spinal cord, the sacral nerves reflect how signals travel through the injured spinal cord. Sacral assessment is therefore essential to determine the level and severity of the spinal cord injury, which helps selecting the proper treatment and predicting recovery (worse when abnormal sacral function. The current assessment relies solely on a manual evaluation, which depends heavily on the physician's experience and does not provide any quantitative value of the dysfunction. The lack of a quantitative method adapted to the clinical setting is a major barrier limiting our knowledge on the impact of sacral function on recovery. We have recently developed an electrophysiological method providing quantitative sacral assessment at bedside after spinal cord injuries. Using this method, we will quantify sacral function in 250 patients with acute spinal cord injuries, and determine its association with recovery 6 months post-injury. We hypothesize that sacral function assessed early within the first 6 weeks after the injury with our method is associated with a better 6-month recovery of motor, sensory, bowel and bladder function. Our objectives are to assess the changes is sacral function during the first 6 months after the injury, and the relationship between early sacral function and 6-month recovery. Sacral function and recovery will be assessed up to 6 months post-injury by the attending physician, in order to measure the electromyographic magnitude of voluntary anal contraction, electromyographic magnitude of anal contraction elicited through sacral reflex testing, and minimal electrical stimulation for which anal sensation is present. The analysis will determine if and how sacral function evolves in time, and if there are specific quantitative criteria of sacral function that physicians can use to determine if patient will have a favorable recovery. conditions: Spinal Cord Injuries conditions: Neurogenic Bowel conditions: Neurogenic Bladder Dysfunction studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 450 type: ESTIMATED name: Sacral electromyography measure: Precise assessment and evaluation of neuro-sacral dysfunction measure: Assessment of clinical phenotypes measure: Clinical prognosis assessment sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hôpital du Sacré-Coeur de Montréal city: Montréal state: Quebec zip: H4J 1C5 country: Canada lat: 45.50884 lon: -73.58781 hasResults: False